The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa

A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa

2000 • 1,513 citations

Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

2001 • 1,379 citations

A MODIFICATION OF RECEPTOR THEORY

1956 • 1,126 citations

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease

2004 • 557 citations

Molecular mechanisms of L-DOPA-induced dyskinesia

2008 • 493 citations

Levodopa motor complications in Parkinson's disease

2000 • 466 citations

Drug Efficacy at G Protein–Coupled Receptors

2002 • 315 citations

Limitations of current Parkinson's disease therapy

2003 • 309 citations

Chronic <scp>L</scp>‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)

1995 • 215 citations

Dopamine receptor agonists: Intrinsic activity vs. state of receptor

1983 • 127 citations

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

2003 • 84 citations

Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunities

2008 • 62 citations

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets

2006 • 46 citations

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist

2006 • 39 citations

Partial dopamine agonist therapy of levodopa‐induced dyskinesias

1992 • 37 citations

L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

2007 • 31 citations

Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist

2006 • 24 citations

Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.

1995 • 23 citations

Effects of terguride, a partial D2 agonist, on MPTP‐lesioned parkinsonian cynomolgus monkeys

1993 • 22 citations

D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function

2008 • 20 citations

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

1993 • 17 citations

Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets

1992 • 14 citations

The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model

1988 • 13 citations

Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo

1993 • 9 citations

Antagonist Effect of Terguride in Parkinsonʼs Disease

1991 • 8 citations

Advanced Parkinson's disease

1987 • 5 citations

Terguride in stable Parkinson's disease.

1995 • 3 citations

SLV 308: plasma levels of effective doses in MPTP-treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans

2004 • 1 citations